Somatostatin shows up in growth-hormone textbooks and in depression research, and most people have never heard of it. Here is what the peptide, the neuron named after it, and its five receptors actually do.
Part 19 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Somatostatin is both a brain signal and a body hormone. It comes in two active forms, and it works through five separate receptors, called SST1 through SST5.
- Many inhibitory brain cells are named “SST neurons” because they carry the gene for this peptide, but the cell, the peptide it may release, and the receptor it activates are three different things.
- Approved somatostatin-like medicines, including octreotide, lanreotide, pasireotide, and a radioactive tumor treatment called Lutathera, treat hormone and cancer conditions. None has a psychiatric approval.
- Some studies find lower average somatostatin in the spinal fluid or brain tissue of people with depression or schizophrenia. These are group-level research findings with a lot of variation between studies, not a test that can diagnose one person.
- No approved psychiatric medicine directly targets any of the five somatostatin receptors.
The short answer
Somatostatin is a peptide, meaning a short chain of amino acids, and it does two jobs at once: it works as a local brain signal and as a hormone that travels through the blood. The body makes two main active versions, somatostatin-14 and somatostatin-28, cut from one larger starting protein.
In the brain, many of the neurons that make somatostatin belong to a well-known class of inhibitory cells, cells that calm other neurons down. Because they carry the gene for this peptide, scientists call them SST neurons. Here is the part that trips people up: an SST neuron’s main, fast job is usually releasing a completely different chemical, GABA. It may release somatostatin too, under different conditions, more slowly. Finding an SST neuron in a tissue sample does not prove that somatostatin itself was released at any particular moment.
Five receptors, named SST1 through SST5, respond to the peptide once it is released. All five generally quiet things down, whether that means less hormone secretion, less cell activity, or less of another chemical being released, but exactly how much and where depends heavily on which of the five receptors is involved and which tissue it sits in.8
Approved somatostatin-like medicines exist, but they treat hormone and tumor conditions, not psychiatric ones. Some studies of people with depression or schizophrenia report lower average somatostatin measurements. That is a real research finding at the group level. It is not a lab test that can diagnose an individual, and no approved psychiatric medicine works by directly correcting somatostatin signaling.
This is the single most useful distinction in this whole topic. A neuron, a chemical messenger, and a docking site for that messenger sound like they should be one story. They are not.
The cell: many inhibitory neurons in the brain’s outer layer, the cortex, express the gene for somatostatin, which is why researchers label them SST neurons. Their headline job is fast inhibition using GABA, the brain’s main calming chemical. They land on specific parts of nearby neurons and shape how those cells combine incoming signals.
The peptide: somatostatin itself is stored differently than GABA. It sits in a different kind of package inside the cell, one that generally needs a stronger or more sustained burst of activity before it gets released. So an SST neuron can be perfectly healthy and active, doing its GABA job constantly, while releasing somatostatin only occasionally.
The receptor: once somatostatin is released, it has to find one of five receptor types to do anything. A receptor sitting in a hormone-producing gland behaves nothing like the same receptor family sitting on a cortical neuron. Same peptide, same receptor family name, very different jobs depending on location.
Put together, a lab finding of “less SST gene activity” in a tissue sample tells you about the cell. It does not directly tell you how much peptide was released, or how active the relevant receptors were, in a living, thinking brain.1
Meet the receptor family
| Receptor | Basic action, where it matters, and why you might care |
|---|---|
| SST1 | Basic action: Generally reduces cell activity and secretion. Where it matters: Brain, pituitary, gut, and other endocrine tissue. Why you might care: Part of the receptor mix that broad-acting analogs touch. |
| SST2 | Basic action: Reduces secretion and can change cell excitability. Where it matters: Pituitary and neuroendocrine tumors, plus cortex, hippocampus, and amygdala. Why you might care: The main current target for hormone and tumor medicines. |
| SST3 | Basic action: Reduces cell activity, with some cell-structure-related effects. Where it matters: Brain and endocrine tissue. Why you might care: Limited direct relevance to psychiatric care so far. |
| SST4 | Basic action: Can change pain signaling, inflammation, and neural activity in animal studies. Where it matters: Brain, sensory nerves, and immune tissue. Why you might care: The target of an experimental pain drug; no psychiatric medicine has followed from it. |
| SST5 | Basic action: Strongly reduces hormone secretion. Where it matters: Pituitary, pancreas, and selected brain sites. Why you might care: The biggest source of differences between analog medicines and their endocrine side effects. |
None of the five receptors is more “important” than another in an absolute sense. SST2 and SST5 currently have the clearest links to real medicines. SST4 draws research interest because animal studies hint at pain, anxiety, or mood effects, but animal behavior alone has never established a human antidepressant benefit.
What depression and schizophrenia research actually found
A 2022 review pooled five older spinal-fluid studies of people with unipolar depression, together covering 130 patients and 113 people without depression. On average, somatostatin measured lower in the depression group. But the studies varied enormously from one another. Their statistical measure of that variation, called I², came out at 91 percent, which means the five studies were not simply repeating the same finding in different rooms.2
Separate postmortem studies, meaning tissue examined after death, have reported lower somatostatin gene activity in specific brain regions. One study looked at part of the anterior cingulate cortex in people who had depression. Another, using 200 postmortem brain samples, compared patterns across diagnoses in the prefrontal cortex and found differences tied to schizophrenia.34
These are genuine clues, not proof of a cause. They cannot show whether lower somatostatin activity caused the illness, resulted from it, reflects years of treatment, or simply marks a class of inhibitory cells under strain. Postmortem tissue is also shaped by things unrelated to psychiatric illness: how long after death the sample was taken, medication history, smoking, and general health at the time of death.
The medication-to-signal map
The table below is intentionally short. There is no routine, direct psychiatric somatostatin medicine.
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Octreotide (including Sandostatin LAR Depot) | What it does directly: Somatostatin analog with strong action at SST2 and SST5. Used for: Selected hormone-excess and gastrointestinal conditions. Main tradeoffs: Blood sugar, gallbladder, heart-rhythm, and digestive effects 5. |
| Lanreotide (Somatuline Depot) | What it does directly: Analog favoring SST2, with some activity elsewhere. Used for: Acromegaly and selected neuroendocrine tumors. Main tradeoffs: Blood sugar, gallbladder, heart-rate, and digestive effects. |
| Pasireotide (Signifor) | What it does directly: Analog with broad activity, strongest at SST5. Used for: Cushing disease, in the specified formulation. Main tradeoffs: High blood sugar, liver, cardiac, gallbladder, and other endocrine effects 6. |
| Lutetium Lu 177 dotatate (Lutathera) | What it does directly: Radioactive somatostatin analog that binds receptor-positive tumors and delivers radiation. Used for: Selected neuroendocrine tumors of the gut and pancreas. Main tradeoffs: Radiation effects on bone marrow, kidney, and liver; pregnancy and fertility precautions; approved from age 12 and up. |
| Mazisotine (LY3556050) | What it does directly: Selective SST4 agonist. Used for: Was tested for diabetic nerve pain, not a psychiatric condition. Main tradeoffs: The developer completed a phase 2 trial and removed the drug from its active pipeline in August 2025. It was never approved for anything, psychiatric or otherwise 7. |
Mazisotine is worth remembering precisely because it shows the limits of a promising target. SST4 looked interesting in animal pain and mood research. A real human program tested it for pain, not mood, ran its course, and the sponsor moved on.7 A receptor being interesting in a lab is not the same as a medicine reaching your pharmacy.
Why a side effect does not mean the drug is treating your mood
Follow pasireotide through the body: it activates several somatostatin receptors, strongly including SST5, which lowers hormone release from specific endocrine cells. That is genuinely useful for a person with a hormone-excess disorder. The same action that helps there also dampens some insulin-related signaling elsewhere in the body, which is why high blood sugar is a known tradeoff.6
Nowhere in that chain does the drug pass through a proven effect on mood. Its medical benefit is real, in the specific population it is approved for. Its psychiatric benefit has not been established, because it was never designed to have one. A patient noticing a side effect from an endocrine medicine, or a symptom improving for unrelated reasons, is not evidence that a hidden psychiatric mechanism has kicked in.
Can this be measured in a patient?
Not usefully, for psychiatric purposes. A spinal-fluid sample can report a somatostatin value, but that number does not locate where the peptide came from, does not identify which receptor it reached, and has no validated threshold for diagnosing depression or picking a medicine.
Blood somatostatin is shaped heavily by the pancreas and gut, not the brain, along with rapid breakdown and the timing of the blood draw. Postmortem tissue studies are valuable for research but cannot guide an individual’s medication choice, because they cannot separate cause from effect or account for everything that happened in a person’s life and final illness. Receptor imaging exists and is genuinely useful, but it is built to find hormone-producing tumors, not to scan mood circuits. Genetic tests on the somatostatin gene or its receptors do not report current release or receptor activity, and no genetic test selects a psychiatric medicine based on this system.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild nausea, abdominal discomfort, loose stool, or injection-site symptoms from an analog medicine. Log the timing and the exact product.
Call the prescriber or pharmacist promptly: persistent vomiting, a marked change in blood sugar, yellowing of the skin or eyes, severe abdominal pain, symptoms of a slow or irregular heartbeat, faintness, or a concerning drug interaction. These need product-specific review.
Call Poison Control at 1-800-222-1222 for a suspected overdose or accidental ingestion. The exact drug and formulation guide the response.
Call 911 now for collapse, seizure, inability to wake someone, severe confusion, trouble breathing, or unstable chest pain. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
What to ask your prescriber
These are conversation starters, not instructions.
- Is this medicine treating a hormone, digestive, tumor, pain, or psychiatric target?
- Which somatostatin receptor subtypes does it act on at the dose I’m taking?
- Which of its effects are direct, and which are downstream?
- What improvement should show up first, and how will we track it?
- What glucose, gallbladder, heart, liver, or hormone monitoring goes with this specific medicine?
- What should I do if I miss a dose?
- Could stopping this medicine suddenly make the condition it treats worse?
- How will we decide together whether the benefit is worth continuing?
Bottom line
Somatostatin is a real, active signal in the brain and body, but “somatostatin neuron,” “somatostatin peptide level,” and “somatostatin receptor activity” are three different measurements that get blurred together in casual conversation. Research groups with depression or schizophrenia show lower averages on some of these measures, with a lot of scatter between studies, which is a clue worth investigating, not a diagnosis you can carry into a doctor’s office. Every somatostatin medicine that exists today treats a hormone or tumor condition. Ask what a lab value or a drug actually measures and treats before assuming it says anything about your mood. For the broader idea that no single brain chemical works alone, see Your Brain Is Not a Gas Tank.
Frequently asked questions
Does depression mean my somatostatin is low?
No. Small group studies have found lower averages in one fluid or tissue sample. That does not diagnose an individual or explain the cause of anyone’s symptoms.
Is an SST neuron the same thing as the somatostatin peptide?
No. The neuron is identified by a gene it carries and its fast GABA signaling. The peptide it may also release, and how active its receptors are, are separate layers of the story.
Can a spinal-fluid test help pick my antidepressant?
No. Spinal-fluid somatostatin has no validated role in diagnosing depression or choosing a treatment for an individual.
Why not just try octreotide or another analog for depression?
These medicines are approved for hormone and tumor conditions, can cause real body-wide side effects like high blood sugar and gallbladder problems, and have no established psychiatric benefit.
If SST4 drugs look promising for mood in animals, isn’t that enough to try one?
No. A real human psychiatric program would need evidence the drug reaches the right brain target safely, a controlled trial, and replication. Mazisotine, tested for pain rather than mood, was removed from its sponsor’s pipeline in 2025 rather than reaching that stage.7
Does a side effect from a somatostatin analog mean it’s working on my mood?
No. Glucose changes, gallbladder symptoms, or heart-rhythm effects are direct target effects of the drug on the body. They say nothing about mood.
Do current antidepressants raise somatostatin directly?
No class-wide direct receptor action has been established. Any change measured after treatment with an existing psychiatric medicine is downstream, uncertain, or specific to one drug and one study.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- What Benzodiazepines Actually Do to the Brain’s Brakes
- When a Drug Hits Its Target and Still Fails
- The Resilience Chemical Nobody Can Measure
References
1. Human SST-neuron and somatostatin biology review. PMID: 35665897
2. Systematic review and meta-analysis of cerebrospinal fluid somatostatin in unipolar depression. JAMA Psychiatry. 2022. Accessed August 31, 2026. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2791250
3. Postmortem study of somatostatin gene expression in the subgenual anterior cingulate cortex in depression. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC3039077/
4. 2023 postmortem study of somatostatin gene expression across diagnoses in dorsolateral prefrontal cortex. JAMA Psychiatry. Accessed August 31, 2026. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2808723
5. Octreotide prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9
6. Pasireotide (Signifor) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
7. Mazisotine (LY3556050) trial registry record and sponsor pipeline update, August 2025. ClinicalTrials.gov NCT06074562. Accessed August 31, 2026. https://clinicaltrials.gov/study/NCT06074562. Sponsor pipeline update: https://investor.lilly.com/static-files/b7c7e82b-e667-42ba-827c-1faecba3e4c8
8. IUPHAR/BPS Guide to Pharmacology, somatostatin receptor family. Accessed August 31, 2026. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, share, combine, or change a somatostatin analog, psychiatric medicine, supplement, or other treatment because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.